Clinical trialPhase 2 / Phase 3Completed
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
- Outcome
- Finished, no results posted
- Phase
- Phase 2 / Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- November 2004
- Expected end
- 30 June 2010
- Enrollment
- 342 participants
- Sites
- 55
- Primary outcomes
- Objective response rate (Phase II); Survival (Phase III)
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 March 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Registry-listed results paperFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- Builds on itResponse to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 r… DOI 10.1371/journal.pone.0183288↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.